Mark Cheah

Dr. Mark Cheah

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Hepatology International
Verified
Journal Article
Open access
PDF file
MCMark Cheah
Mark Cheah
HCHarry Crane
Harry Crane
JGJacob George
Jacob George
Background: Metabolic Dysfunction-Associated Fatty Liver disease (MAFLD) among lean individuals is increasingly recognized. We aimed to compare the prevalence, metabolic characteristics, and outcomes of lean vs overweight/obese-MAFLD patients. Methods: Databases of Embase, Medline, and Web of Science were searched from inception till October 2023. Only cohorts adhering to the lean-MAFLD criteria as defined by the international consensus statement were included. Results: In the pooled analysis of 10,013,382 individuals, the prevalence of lean-MAFLD in the general population was 1.94% (95% CI 1.10–3.39%, I 2 = 98.7%). Lean and overweight/obese-MAFLD patients had similar metabolic characteristics for blood pressure, LDL, TG, blood glucose, and HbA1c. There was an increased incidence rate and likelihood for liver-related mortality for lean-MAFLD vs overweight/obese-MAFLD [1.33 per 1000 patient-years (95% CI 1.28–1.39) vs 0.76 (95% CI 0.25–2.28), (OR 3.56 (95% CI 3.45–3.67), p < 0.01). There were similar incidence rates and odds ratios between lean vs overweight/obese-MAFLD for: (1) all-cause mortality [10.08 per 1000 patient-years (95% CI 9.93–10.23) vs 8.94 per 1000 patient-years (95% CI 4.08–19.57), (OR 1.92 (95% CI 0.01–220.57), p = 0.33)]; (2) cardiovascular-related mortality [2.53 per 1000 patient-years (95% CI 0.65–9.96) vs 2.07 per 1000 patient-years (95% CI 0.80–5.39), (OR 1.91 (95% CI 0.02–142.76), p = 0.58)]; and (3) cancer-related mortality [3.42 per 1000 patient-years (95% CI 3.33–3.51) vs 3.15 per 1000 patient-years (95% CI 1.21–8.19), (OR 1.99 (95% CI 0.29–13.52), p = 0.13). Conclusion: Lean-MAFLD patients have an equivalent metabolic burden compared to overweight/obese-MAFLD patients and thus a similar incidence rate of major extrahepatic complications. However, they have an increased risk of liver-related mortality. Graphical

13 August 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MCMark Cheah
Mark Cheah
BGB. B. George Goh
B. B. George Goh

20 December 2024 in JGH Open
Verified
Journal Article
Open access
JHJonas Ho
Jonas Ho
RRR Rajesh
R Rajesh
WWWei Keat Wan
Wei Keat Wan
MCMark Cheah
Mark Cheah
YTYi Yuan Tan
Yi Yuan Tan
Background: Linitis plastica is a challenging diagnosis in the setting of a patient with previous breast cancer.Case presentation: We present a case of a 74‐year‐old Chinese Female with a history of breast cancer who presented with epigastric pain, nausea, early satiety, and weight loss of 5 kg in 3 months. Endoscopic diagnosis of linitis plastica was made, but subsequent management plans were dependent on accurate histological assessment in view of her oncological history.Discussion and conclusion: Our case highlights the clinical conundrum confronting the endoscopist in evaluating suspected linitis plastica where the imaging, endoscopic, and macroscopic histological findings between primary gastric adenocarcinoma and metastatic breast cancer can be indistinguishable. Optimal deep tissue acquisition is required to differentiate the true diagnosis in such cases.

18 January 2021 in Journal of Telemedicine and Telecare
Verified
Journal Article
Closed access
PDF file
RKRajneesh Kumar
Rajneesh Kumar
MYMei-Ling Yee
Mei-Ling Yee
GGGeorge Bb Goh
George Bb Goh
PCPei-Yuh Chia
Pei-Yuh Chia
HLHwei-Ling Lee
Hwei-Ling Lee
WCWan-Cheng Chow
Wan-Cheng Chow
Chronic hepatitis B (CHB) remains common in endemic regions, causing significant healthcare burden. Patients with CHB may need to be adherent to nucleoside analogue (NA) for a long period of time to prevent complications. This study aims to investigate the safety, efficacy and patient experience of a virtual monitoring clinic (VMC) in monitoring stable patients taking NA for CHB. Patients on NA and regular follow-up were randomised to either VMC alternating with doctors’ clinic visit or to a control group in which they continued standard follow-up by doctors. Therapy adherence was measured by medication possession ratio (MPR) for NA therapy, incidence of virological breakthrough and hepatocellular carcinoma (HCC) development at two years of follow-up. Patient acceptance was measured on a Likert scale of 1–10. A total 192 patients completed follow-up: 94 and 98 patients in the VMC and control groups, respectively. Mean age was 60.6 ± 10.8 years, with 95.3% Chinese ethnicity and 64.1% males. Age, gender, race, educational, employment and financial status were similar in both groups. Upon study completion, the majority of patients – 76 (80.9%) in VMC group and 74 (75.5%) in control group – had MPR ≥0.8; 88.8% were satisfied and rated VMC better than a traditional follow-up clinic with doctors only. More than 85% of patients rated ≥8/10 on the Likert scale for VMC, and preferred VMC over traditional clinic visits. Clinical outcomes observed were HCC development in one (1.1%) in the VMC group and four (4.1%) in the control group (p = 0.369). Two (2.1%) and one (1.0%) virological breakthroughs were observed in the VMC and control groups, respectively (p = 0.615). No incidence of HCC or abnormal blood tests were missed in the VMC arm. VMC is a viable and safe clinical model for monitoring stable CHB patients on NA therapy without compromising patients’ adherence to medications and is preferred by patients.

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
BSBenedix Sim
Benedix Sim
MCMark Cheah
Mark Cheah
PCPak Wo Chan
Pak Wo Chan
MTMalcolm Tan
Malcolm Tan
HSHang Hock Shim
Hang Hock Shim
ESEnnaliza Salazar
Ennaliza Salazar

16 February 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
MCMark Cheah
Mark Cheah
GGGeorge Goh
George Goh